HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A carrier-free metal-organic hybrid nanoassembly with combination anti-viral and hepato-protective activity for hepatitis B treatment.

Abstract
Hepatitis B represents a major global public health burden, which is caused by the hepatitis B virus (HBV) with a high infection rate. Although several anti-HBV drugs have been developed for clinical treatment of hepatitis B, the current therapeutic strategies still suffer from undeniable adverse effects, insufficient efficacy after systemic administration and chronic inflammation. Here, we develop a carrier-free metal-organic hybrid nanoassembly that is co-loaded with tenofovir (TFV), an anti-viral agent and phosphorylated glycyrrhetinic acid (GAP), an anti-inflammatory compound (TFV/GAP/NA) to enhance the anti-HBV effect and alleviate the inflammatory response for hepatitis B treatment. The nanoassembly is easily prepared through the ionic interactions between the anionic phosphonate/phosphate groups from TFV/GAP and the zirconium cation, which has a stable nanostructure and a high drug-loading capacity. The nanoassembly prolongs the circulation time with reduced drug leakage in the blood and elevates drug accumulation in the liver after intravascular administration. After internalization mediated by the GAP ligand-GA receptor interaction, TFV/GAP/NA disassembles by the phosphatase-triggered degradation of the phosphate ester bonds in GAP and releases TFV, GAP and GA within the HBV-positive hepatocytes. The released TFV interferes with the HBV polymerase to inhibit the viral DNA replication, while the released GAP and GA suppress the pro-inflammatory protein expression. In mouse models, treatment with TFV/GAP/NA inhibits HBV production and alleviates inflammation-mediated liver injury.
AuthorsHe Dong, Xiaodan Hong, Yingjiao He, Zhengxiang Bao, Ying Zhang, Shiyang Shen, Guangji Wang, Jingwei Zhang, Ran Mo
JournalBiomaterials science (Biomater Sci) Vol. 10 Issue 15 Pg. 4356-4366 (Jul 26 2022) ISSN: 2047-4849 [Electronic] England
PMID35786722 (Publication Type: Journal Article)
Chemical References
  • Antiviral Agents
  • DNA, Viral
  • Organophosphates
  • Phosphates
  • Tenofovir
  • Adenine
Topics
  • Adenine (pharmacology)
  • Animals
  • Antiviral Agents (pharmacology)
  • DNA Replication
  • DNA, Viral (pharmacology, therapeutic use)
  • Hepatitis B (drug therapy)
  • Hepatitis B virus (metabolism)
  • Inflammation (drug therapy)
  • Mice
  • Organophosphates
  • Phosphates
  • Tenofovir (pharmacology, therapeutic use)
  • Virus Replication

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: